Nitrogen-mustard therapy for Hodgkin's disease, lymphosarcoma, the leukemias, and other disorders.
作者信息
WINTROBE M M, HUGULEY C M
出版信息
Cancer. 1948 Sep;1(3):357-82. doi: 10.1002/1097-0142(194809)1:3<357::aid-cncr2820010303>3.0.co;2-v.
Abstract
摘要
相似文献
1
Nitrogen-mustard therapy for Hodgkin's disease, lymphosarcoma, the leukemias, and other disorders.
Cancer. 1948 Sep;1(3):357-82. doi: 10.1002/1097-0142(194809)1:3<357::aid-cncr2820010303>3.0.co;2-v.
2
The use of nitrogen mustard in Hodgkin's disease and lymphosarcoma.
Ann Intern Med. 1949 Feb;30(2):381-6. doi: 10.7326/0003-4819-30-2-381.
3
4
Nitrogen mustard as a therapeutic agent for Hodgkin's disease, lymphosarcoma and leukemia.
Ann Intern Med. 1947 Oct;27(4):529-40. doi: 10.7326/0003-4819-27-4-529.
5
[Nitrogen mustard in the treatment of Hodgkin's disease, lymphosarcoma, leukemia and related diseases].
Arq Clin (Rio De J). 1951 Mar;12(3):141-61.
6
Nitrogen mustard therapy in Hodgkin's disease, lympho-reticulosarcomatosis and lymphatic leukaemia.
Acta Radiol (Stockh). 1951 Dec;36(6):461-8. doi: 10.3109/00016925109176998.
7
Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders.
J Am Med Assoc. 1946 Sep 21;132:126-32. doi: 10.1001/jama.1946.02870380008004.
8
[Effect of methyl-bis (beta-chloroethyl)amine hydrochloride on Hodgkin's disease, lymphosarcoma, leukemia and neoplasms].
Riv Patol Clin. 1951 Jan;6(1):1-58.
9
[Nitrogen mustard therapy of proliferative blood diseases; methods, experiences as well as application possibilities in therapy of carcinoma].
Wien Med Wochenschr. 1953 Jan 3;103(1):11-4.
10
[Nitrogen mustard therapy of various cases of malignant lymphogranuloma and lymphosarcoma].
Accad Medica. 1952 Apr;67(4):169-77.
引用本文的文献
1
Anthrax: Transmission, Pathogenesis, Prevention and Treatment.
Toxins (Basel). 2025 Jan 24;17(2):56. doi: 10.3390/toxins17020056.
2
Clinical practice guideline-inconsistent chemotherapy-induced vomiting prophylaxis in pediatric cancer patients in community settings: A Children's Oncology Group study.
Pediatr Blood Cancer. 2024 Nov;71(11):e31295. doi: 10.1002/pbc.31295. Epub 2024 Sep 5.
3
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.
Oncoimmunology. 2022 May 26;11(1):2077898. doi: 10.1080/2162402X.2022.2077898. eCollection 2022.
4
Professional educational needs for chemotherapy-induced nausea and vomiting (CINV): multinational survey results from 2388 health care providers.
Support Care Cancer. 2015 Jan;23(1):151-7. doi: 10.1007/s00520-014-2325-x.
5
Maxwell Myer Wintrobe: new history and a new appreciation.
Tex Heart Inst J. 2007;34(3):328-35.
Zotero 插件